Member Article

Clatterbridge Cancer Centre benefits from £10,000 Flextronics donation

A Cheshire-based centre renowned for its pioneering cancer treatments has been given a major boost thanks to a £10,000 donation from Flextronics in Warrington.

The Clatterbridge Cancer Centre, which has nine operating sites across Cheshire and Merseyside, was announced as Flextronics’ official ‘Charity of the Year 2014’ and awarded £10,000 to help it continue its work as one of the largest networked Cancer Centres in the UK.

Clatterbridge was the winner in a ‘Dragon’s Den’ style competition where staff at Flextronics were invited to choose a cause close to their hearts and pitch to company bosses. A panel of managers then had the difficult task of deciding which charity the supply chain solutions specialists would partner with for the next 12 months.

Flextronics General Manager, Mike Meades, said: “We’re very pleased to be backing The Clatterbridge Cancer Centre as our Charity of the Year for 2014.

“They say one in three people will be affected by cancer during their lifetime and research and treatment centres such as Clatterbridge offer vital support and treatments for those dealing with the disease.

“We know that Clatterbridge is a centre many of our employees have had personal experience with and, although all of the charities nominated were very worthy causes, there was a lot of staff support for Clatterbridge.

“We’re now investigating more ways that we can get involved with the organisation and we’re looking forward to making a significant contribution to the work that goes on there.”

The partnership was officially launched at a charity day held at Flextronics’ Warrington headquarters, where Clatterbridge staff were presented with a cheque for £10,000 and spoke to Flextronics employees about fundraising opportunities.

Jade Barrett, Area Fundraising Manager at The Clatterbridge Cancer Centre, said: “We are absolutely delighted to have been chosen by Flextronics as their Charity of the Year and I’d like to thank everybody at the company for thinking of us.

“The partnership has begun with an incredibly generous donation which will help us fund vital research, new equipment and continue support services that may otherwise be unavailable.

“There’s a fantastic programme of fundraising events coming up, which Flextronics is lending its support to, and we’re excited about what we can achieve together for Clatterbridge cancer patients and their families over the coming months.”

For more information about Flextronics, visit: www.flextronics.com

Ends

For further information, contact Lee Cullen or Elle Brunton on the Flextronics PR team at de Winter PR on 01244 320677, or email lee@thinkdewinter.co.uk or elle@thinkdewinter.co.uk

About Flextronics

Flextronics (Reg. No. 199002645H) is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories.

Flextronics is an industry leader with $26 billion in sales, generated from helping customers design, build, ship, and service their products through an unparalleled network of facilities in approximately 30 countries and across four continents. Flextronics service offerings and vertically integrated component technologies optimize customer supply chains by lowering costs, increasing flexibility, and reducing time-to-market. For more information, visit www.flextronics.com or follow us on Twitter @flextronics.

About The Clatterbridge Cancer Centre

The Clatterbridge Cancer Centre is one of the largest networked cancer centres in the UK.

From nine operating sites across Merseyside and Cheshire it treats over 30,000 patients a year, offering pioneering chemotherapy, radiotherapy and proton therapy treatment.

Clatterbridge brings together high-quality clinical services, research and academic excellence to drive forward the development of new leading edge drugs and therapies and provide the best specialist care for patients.

This was posted in Bdaily's Members' News section by Elle Brunton .